Free Trial
TSE:CRDL

Cardiol Therapeutics Q1 2026 Earnings Results & Report

Cardiol Therapeutics logo
C$1.64 -0.07 (-4.09%)
As of 12:47 PM Eastern

Cardiol Therapeutics reported Q1 2026 earnings on May 11, 2026. The company reported EPS of -C$0.10.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Cardiol Therapeutics EPS Results

Actual EPS
-C$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cardiol Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardiol Therapeutics Q1 2026 Earnings FAQ

Cardiol Therapeutics (TSE:CRDL) reported earnings of -C$0.10 per share for Q1 2026. The report was announced on Monday, May 11, 2026.

Cardiol Therapeutics Earnings Headlines

INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.tc pixel
See More Cardiol Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiol Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiol Therapeutics and other key companies, straight to your email.

About Cardiol Therapeutics

Cardiol Therapeutics (TSE:CRDL) ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299).

View Cardiol Therapeutics Profile